Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Parkinson's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 127 articles:
HTML format



Single Articles


    September 2022
  1. SIEGLER JE 3RD, Galetta S
    Editors' Note: Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
    Neurology. 2022;99:585.
    PubMed    


  2. OVEISGHARAN S, Bennett DA, Buchman AS
    Author Response: Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
    Neurology. 2022;99:586.
    PubMed    


  3. KELLER DL
    Reader Response: Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
    Neurology. 2022;99:585.
    PubMed    


  4. SASAKI R, Morimoto S, Ozawa F, Okano H, et al
    APOE Alleles With Tau and Abeta Pathology In Patients With Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex in the Kii Peninsula.
    Neurology. 2022 Sep 21. pii: WNL.0000000000201156.
    PubMed     Abstract available


  5. MAJBOUR N, Aasly J, Abdi I, Ghanem S, et al
    Disease-Associated alpha-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage.
    Neurology. 2022 Sep 12. pii: WNL.0000000000201199.
    PubMed     Abstract available


    August 2022
  6. LEWIS A, Galetta S
    Editors' Note: Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Neurology. 2022;99:403.
    PubMed    


  7. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Author Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:402.
    PubMed    


  8. BRENNER SR
    Reader Response: Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Neurology. 2022;99:403.
    PubMed    


  9. LEWIS A, Galetta S
    Editors' Note: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:401.
    PubMed    


  10. GRIPPE TC, Marras C, Rafferty M, Lang AE, et al
    Reader Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:401-402.
    PubMed    


  11. LIN CH, Chen SJ, Kuo CH
    Author Response: Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Neurology. 2022;99:404.
    PubMed    


  12. TOSSERAMS A, Keijsers N, Kapelle W, Kessels RPC, et al
    Evaluation of Compensation Strategies for Gait Impairment in Patients With Parkinson Disease.
    Neurology. 2022 Aug 25. pii: WNL.0000000000201159.
    PubMed     Abstract available


  13. SAUNDERS-PULLMAN R, Ortega RA, Wang C, Raymond D, et al
    Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant.
    Neurology. 2022;99:e814-e823.
    PubMed     Abstract available


  14. CROTTY GF, Schwarzschild MA
    What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.
    Neurology. 2022;99.
    PubMed     Abstract available


  15. MOLSBERRY SA, Hughes KC, Schwarzschild MA, Ascherio A, et al
    Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts.
    Neurology. 2022;99.
    PubMed     Abstract available


  16. MIRELMAN A, Siderowf A, Chahine L
    Outcome Assessment in Parkinson Disease Prevention Trials: Utility of Clinical and Digital Measures.
    Neurology. 2022;99.
    PubMed     Abstract available


  17. SEIBYL JP, Kuo P
    What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?
    Neurology. 2022;99.
    PubMed    


  18. MACKLIN EA, Coffey CS, Brumm MC, Seibyl JP, et al
    Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease.
    Neurology. 2022;99.
    PubMed     Abstract available


  19. POSTUMA RB
    Neuroprotective Trials in REM Sleep Behavior Disorder: The Way Forward Becomes Clearer.
    Neurology. 2022;99.
    PubMed     Abstract available


  20. BERG D, Crotty GF, Keavney JL, Schwarzschild MA, et al
    Path to Parkinson Disease Prevention: Conclusion and Outlook.
    Neurology. 2022;99.
    PubMed     Abstract available


  21. NIOTIS K, West AB, Saunders-Pullman R
    Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts.
    Neurology. 2022;99.
    PubMed     Abstract available


  22. JANSSEN DAALEN JM, Schootemeijer S, Richard E, Darweesh SKL, et al
    Lifestyle Interventions for the Prevention of Parkinson Disease: A Recipe for Action.
    Neurology. 2022;99.
    PubMed     Abstract available


  23. GROVER S, Kumar Sreelatha AA, Pihlstrom L, Domenighetti C, et al
    Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium.
    Neurology. 2022;99:e698-e710.
    PubMed     Abstract available


  24. PALMA JA
    Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:260.
    PubMed    


  25. KANG UJ, Nakamura K, Zhuang X
    Reader Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:258-259.
    PubMed    


  26. CHRISTINE CW, Richardson RM, Van Laar A, Fine EM, et al
    Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:260-261.
    PubMed    


  27. CHRISTINE CW, Richardson RM, Fine EM, Khwaja OS, et al
    Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:259.
    PubMed    


  28. SIEGLER JE, Galetta S
    Editors' Note: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2022;99:258.
    PubMed    


  29. BELLOMO G, De Luca CMG, Paoletti FP, Gaetani L, et al
    alpha-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
    Neurology. 2022;99:195-205.
    PubMed     Abstract available


    July 2022
  30. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Author Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:132.
    PubMed    


  31. LEWIS A, Galetta S
    Editors' Note: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:131.
    PubMed    


  32. DARWEESH SKL, De Vries N, Bloem BR
    Reader Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:131-132.
    PubMed    


  33. GUPTA VK
    Reader Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:133.
    PubMed    


  34. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Author Response: Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022;99:133-134.
    PubMed    


  35. TAKEUCHI H, Masaki K, Ogata H, Nagata S, et al
    Teaching NeuroImages: Reversible Parkinsonism Caused by Lumboperitoneal Shunt Overdrainage.
    Neurology. 2022 Jul 8. pii: WNL.0000000000200994.
    PubMed    


    June 2022
  36. BERGQUIST F, Ehrnebo M, Nyholm D, Johansson A, et al
    Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease.
    Neurology. 2022 Jun 15. pii: WNL.0000000000200804.
    PubMed     Abstract available


  37. YOON EJ, Lee JY, Kim H, Yoo D, et al
    Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder.
    Neurology. 2022;98:e2413-e2424.
    PubMed     Abstract available


  38. WANG L, Wu P, Brown P, Zhang W, et al
    Association of Structural Measurements of Brain Reserve With Motor Progression in Patients With Parkinson Disease.
    Neurology. 2022 Jun 6. pii: WNL.0000000000200814.
    PubMed     Abstract available


    May 2022
  39. TALMAN L
    Quality of Life for Patients With Parkinson Disease.
    Neurology. 2022;98:e2293-e2295.
    PubMed    


  40. GROVER S, Ashwin AKS, Pihlstrom L, Domenighetti C, et al
    Genome-wide Association and Meta-analysis of Age-at-Onset in Parkinson Disease: Evidence From COURAGE-PD Consortium.
    Neurology. 2022 May 26. pii: WNL.0000000000200699.
    PubMed     Abstract available


  41. AVENALI M, Vaghi G, De Icco R, Grillo V, et al
    Pearls & Oy-sters: Marionette walk in Parkinson's disease: a rare dyskinetic-dystonic gait pattern complication improved by visual cueing.
    Neurology. 2022 May 18. pii: WNL.0000000000200714.
    PubMed     Abstract available


    April 2022
  42. LIN J, Li C, Shang H
    Teaching Video NeuroImage: Oculogyric Crises in a 12-Year-Old Girl With Rapid-Onset Dystonia Parkinsonism.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200584.
    PubMed    


  43. DELGADO-ALVARADO M, Gutierrez-Gonzalez A, Marques-Llano S, Riancho J, et al
    Parkinsonism Associated With Striatal Enlarged Perivascular Spaces.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200547.
    PubMed    


  44. CHEN TX, Roy Lin CY, Aumann MA, Yan Y, et al
    Impulsivity Trait Profiles in Patients With Cerebellar Ataxia and Parkinson Disease.
    Neurology. 2022 Apr 15. pii: WNL.0000000000200349.
    PubMed     Abstract available


  45. MYERS PS, O'Donnell JL, Jackson JJ, Lessov-Schlaggar CN, et al
    Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200344.
    PubMed     Abstract available


  46. BOCK MA, Brown EG, Zhang L, Tanner C, et al
    Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200113.
    PubMed     Abstract available


  47. HALLOWAY S, Desai P, Beck T, Aggarwal N, et al
    Association of Neurofilament Light With the Development and Severity of Parkinson Disease.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200338.
    PubMed     Abstract available


    March 2022
  48. OVEISGHARAN S, Yu L, Barnes LL, Agrawal S, et al
    Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200182.
    PubMed     Abstract available


    February 2022
  49. GONCALVES A, Oliveira J, Simoes R, Canas N, et al
    Hemiparkinsonism Secondary to Giant Aneurysm.
    Neurology. 2022;98:325-326.
    PubMed    


  50. CHUNG SJ, Kim YJ, Jung JH, Lee HS, et al
    Association Between White Matter Connectivity and Early Dementia in Patients With Parkinson Disease.
    Neurology. 2022 Feb 21. pii: WNL.0000000000200152.
    PubMed     Abstract available


  51. ARMENTEROS PR, Kapetanovic S, Lopez SG, Vazquez-Lorenzo E, et al
    Pearls & Oy-sters: Arteriovenous Malformation With Sinus Thrombosis and Thalamic Hemorrhage: Unusual Cause of Parkinsonism and Dementia.
    Neurology. 2022 Feb 4. pii: WNL.0000000000200016.
    PubMed     Abstract available


    January 2022
  52. ZHANG X, Molsberry SA, Yeh TS, Cassidy A, et al
    Intake of Flavonoids and Flavonoid-Rich Foods, and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study.
    Neurology. 2022 Jan 26. pii: WNL.0000000000013275.
    PubMed     Abstract available


  53. PAAKINAHO A, Koponen M, Tiihonen M, Kauppi M, et al
    Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis.
    Neurology. 2022 Jan 21. pii: WNL.0000000000013303.
    PubMed     Abstract available


  54. MAK MK, Schwarz HB
    Could Exercise Be the Answer? Disease-Modification With Long-term Regular Physical Activity in Parkinson Disease.
    Neurology. 2022 Jan 12. pii: WNL.0000000000013208.
    PubMed    


  55. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease.
    Neurology. 2022 Jan 12. pii: WNL.0000000000013218.
    PubMed     Abstract available


  56. PROVITERA V, Iodice V, Manganelli F, Mozzillo S, et al
    Postganglionic Sudomotor Assessment in Early Stage of Multiple System Atrophy and Parkinson Disease: A Morpho-functional Study.
    Neurology. 2022 Jan 11. pii: WNL.0000000000013300.
    PubMed     Abstract available


  57. CHEN SJ, Chen CC, Liao HY, Lin YT, et al
    Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients.
    Neurology. 2022 Jan 7. pii: WNL.0000000000013225.
    PubMed     Abstract available


  58. HWANG YJ, Alexander GC, Moore TJ, Mehta HB, et al
    Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
    Neurology. 2022;98:49-50.
    PubMed    


  59. SUBBIAH P, Doshi D, Turner ME
    Reader Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
    Neurology. 2022;98:49.
    PubMed    


  60. GANESH A, Galetta S
    Editors' Note: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
    Neurology. 2022;98:48.
    PubMed    


    December 2021
  61. MAIDAN I, Hacham R, Galperin I, Giladi N, et al
    Neural Variability in the Prefrontal Cortex as a Reflection of Neural Flexibility and Stability in Patients With Parkinson Disease.
    Neurology. 2021 Dec 14. pii: WNL.0000000000013217.
    PubMed     Abstract available


    November 2021
  62. PRINGSHEIM T, Day GS, Smith DB, Rae-Grant A, et al
    Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
    Neurology. 2021;97:942-957.
    PubMed     Abstract available


    October 2021
  63. RONG S, Xu G, Liu B, Sun Y, et al
    Trends in Mortality From Parkinson Disease in the United States, 1999-2019.
    Neurology. 2021 Oct 27. pii: WNL.0000000000012826.
    PubMed     Abstract available


  64. BESSE-PINOT E, Pereira B, Durif F, Fantini ML, et al
    Preoperative REM Sleep Behavior Disorder and Subthalamic Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery.
    Neurology. 2021 Oct 19. pii: WNL.0000000000012862.
    PubMed     Abstract available


  65. YOON SY, Park YH, Lee HJ, Kang DR, et al
    Lifestyle Factors and Parkinson Disease Risk: Korean Nationwide Cohort Study With Repeated Health Screening Data.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012942.
    PubMed     Abstract available


  66. CHRISTINE CW, Richardson RM, Van Laar AD, Thompson ME, et al
    Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012952.
    PubMed     Abstract available


  67. RUSZ J, Tykalova T, Novotny M, Zogala D, et al
    Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012878.
    PubMed     Abstract available


    September 2021
  68. SAMOTUS O, Chen R, Jog M
    Changes in Cortical Excitability and Parkinson Tremor After Botulinum Toxin Therapy.
    Neurology. 2021 Sep 8. pii: WNL.0000000000012662.
    PubMed     Abstract available


  69. TOSSERAMS A, Wit L, Sturkenboom IHWM, Nijkrake MJ, et al
    Perception and Use of Compensation Strategies for Gait Impairment by Persons With Parkinson Disease.
    Neurology. 2021 Sep 8. pii: WNL.0000000000012633.
    PubMed     Abstract available


  70. HANTIKAINEN E, Trolle Lagerros Y, Bonn S
    Author Response: Dietary Antioxidants and the Risk of Parkinson Disease: The Swedish National March Cohort.
    Neurology. 2021;97:511-512.
    PubMed    


  71. KAWADA T
    Reader Response: Dietary Antioxidants and the Risk of Parkinson Disease: The Swedish National March Cohort.
    Neurology. 2021;97:511.
    PubMed    


  72. MATAR E, White SR, Taylor JP, Thomas A, et al
    Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.
    Neurology. 2021;97:e1031-e1040.
    PubMed     Abstract available


  73. CHIEN HF, Rodriguez RD, Bonifati V, Nitrini R, et al
    Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa Responsive Parkinsonism Due to ATP13A2 Mutation.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012705.
    PubMed     Abstract available


    August 2021

  74. PARK2, PINK1, and DJ1 in patients with early-onset Parkinson's disease in four European countries.
    Neurology. 2021 Aug 31. pii: WNL.0000000000012715.
    PubMed    


  75. PILOTTO A, Romagnolo A, Scalvini A, Masellis M, et al
    Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders.
    Neurology. 2021;97:e814-e824.
    PubMed     Abstract available


  76. HWANG YJ, Alexander GC, An H, Moore TJ, et al
    Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
    Neurology. 2021 Aug 13. pii: WNL.0000000000012601.
    PubMed     Abstract available


  77. ALI F
    Pimavanserin: A Friend or Foe in Parkinson Disease Psychosis.
    Neurology. 2021 Aug 13. pii: WNL.0000000000012656.
    PubMed    


  78. CHOU KL, Martello J, Atem J, Elrod M, et al
    Quality Improvement in Neurology: 2020 Parkinson Disease Quality Measurement Set Update.
    Neurology. 2021;97:239-245.
    PubMed    


    June 2021
  79. PRASUHN J, Prasuhn M, Fellbrich A, Strautz R, et al
    Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Neurology. 2021 Jun 29. pii: WNL.0000000000012444.
    PubMed     Abstract available



  80. Cross-Sectional Profile of Most Bothersome Problems as Reported Directly by Individuals With Parkinson's Disease (2697).
    Neurology. 2021 Jun 22. pii: WNL.0000000000012412.
    PubMed    


  81. BOVE F, Mulas D, Cavallieri F, Castrioto A, et al
    Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease.
    Neurology. 2021 Jun 2. pii: WNL.0000000000012246.
    PubMed     Abstract available


    May 2021
  82. GANDHI AB, Onukwugha E, Albarmawi H, Johnson A, et al
    Healthcare Resource Utilization Associated With Parkinson Disease Among Medicare Beneficiaries.
    Neurology. 2021 May 27. pii: WNL.0000000000012290.
    PubMed     Abstract available


  83. SHIN JH, Lee JY, Kim YK, Yoon EJ, et al
    Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder.
    Neurology. 2021 May 19. pii: WNL.0000000000012228.
    PubMed     Abstract available


  84. BEACH T, Chahine LM, Adler CH, Mollenhauer B, et al
    Author Response: In Vivo Distribution of alpha-Synuclein in Multiple Tissues and Biofluids in Parkinson Disease.
    Neurology. 2021;96:965-967.
    PubMed    


  85. GIBBONS C, Donadio V, Sommer C, Liguori R, et al
    Reader Response: In Vivo Distribution of alpha-Synuclein in Multiple Tissues and Biofluids in Parkinson Disease.
    Neurology. 2021;96:964-965.
    PubMed    


  86. IRWIN D, Saint-Hilaire M
    In Vivo Detection of Underlying Synucleinopathies: Are We There Yet?
    Neurology. 2021;96:925-926.
    PubMed    


  87. DONADIO V, Wang Z, Incensi A, Rizzo G, et al
    In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
    Neurology. 2021;96:e2513-e2524.
    PubMed     Abstract available


  88. MCCUSKER EA, Loy CT
    Prevalent Nonmotor Symptoms Associated With Huntington Disease: Challenging to Interpret and With Early Impact on Function.
    Neurology. 2021;96:875-876.
    PubMed    


  89. KIM R, Park S, Yoo D, Jun JS, et al
    Association of Physical Activity and APOE Genotype With Longitudinal Cognitive Change in Early Parkinson Disease.
    Neurology. 2021;96:e2429-e2437.
    PubMed     Abstract available


  90. HONG Z, Tian C, Stewart T, Aro P, et al
    Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying alpha-Synuclein-Containing Extracellular Vesicles.
    Neurology. 2021;96:e2332-e2345.
    PubMed     Abstract available


    April 2021
  91. RIOU A, Houvenaghel JF, Dondaine T, Drapier S, et al
    Functional Role of the Cerebellum in Parkinson Disease: A PET Study.
    Neurology. 2021 Apr 28. pii: WNL.0000000000012036.
    PubMed     Abstract available


  92. DONG Y, Cheng X, Dong Q
    Teaching NeuroImages: Parkinsonism Presenting With Watershed Pattern Lesions.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012056.
    PubMed    


  93. LAMOTTE G, Benarroch EE
    What Is the Clinical Correlation of Cardiac Noradrenergic Denervation in Parkinson Disease?
    Neurology. 2021;96:748-753.
    PubMed    


    March 2021
  94. RABER J, Darweesh SKL, Savica R
    Physical Activity May Reduce Apolipoprotein E4-Associated Cognitive Decline in Parkinson Disease.
    Neurology. 2021 Mar 31. pii: WNL.0000000000011851.
    PubMed    


  95. TANG X, Zhang Y, Liu D, Hu Y, et al
    Association of Gyrification Pattern, White Matter Changes, and Phenotypic Profile in Patients With Parkinson Disease.
    Neurology. 2021 Mar 25. pii: WNL.0000000000011894.
    PubMed     Abstract available


  96. HACKER ML, Konrad PE, Davis TL, Charles D, et al
    Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
    Neurology. 2021;96:592.
    PubMed    


  97. SIDIROPOULOS C
    Reader Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
    Neurology. 2021;96:591-592.
    PubMed    


  98. CHARLES D, Hacker ML, Davis TL, Konrad PE, et al
    Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
    Neurology. 2021;96:591.
    PubMed    


  99. FASANO A, Bhowmick SS
    Reader Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
    Neurology. 2021;96:590-591.
    PubMed    


  100. SIEGLER JE, Galetta S
    Editors' Note: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes.
    Neurology. 2021;96:590.
    PubMed    


  101. CHUNG SJ, Yoo HS, Shin NY, Park YW, et al
    Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011797.
    PubMed     Abstract available


    February 2021
  102. LO C, Arora S, Ben-Shlomo Y, Barber TR, et al
    Olfactory Testing in Parkinson's Disease & REM Behavior Disorder: A Machine Learning Approach.
    Neurology. 2021 Feb 24. pii: WNL.0000000000011743.
    PubMed     Abstract available


  103. KANG X, Ploner A, Pedersen NL, Bandres-Ciga S, et al
    Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study.
    Neurology. 2021 Feb 19. pii: WNL.0000000000011630.
    PubMed     Abstract available


  104. PARK KW, Lee EJ, Lee JS, Jeong J, et al
    Machine Learning Based Automatic Rating for Cardinal Symptoms of Parkinson.
    Neurology. 2021 Feb 10. pii: WNL.0000000000011654.
    PubMed     Abstract available


  105. PARK JH, Lee CW, Nam MJ, Kim H, et al
    Association of High-density Lipoprotein Cholesterol Variability and the Risk of Developing Parkinson's Disease.
    Neurology. 2021 Feb 3. pii: WNL.0000000000011553.
    PubMed     Abstract available


  106. PES GM, Park YM, Sechi GP
    Cholesterol trafficking in the brain: Are we overlooking an important risk factor for Parkinson's disease?
    Neurology. 2021 Feb 3. pii: WNL.0000000000011595.
    PubMed    


    January 2021
  107. HANTIKAINEN E, Lagerros YT, Ye W, Serafini M, et al
    Dietary antioxidants and the risk of Parkinson Disease: The Swedish National March Cohort.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011373.
    PubMed     Abstract available


    December 2020

  108. Correction: Cultural disparities in deep brain stimulation (DBS) decision making in patients with Parkinson disease (PD) (1713).
    Neurology. 2020 Dec 22. pii: WNL.0000000000011240.
    PubMed    


  109. MAPLE-GRODEM J, Dalen I, Tysnes OB, Macleod AD, et al
    Association of GBA Genotype with Motor and Functional Decline in Newly Diagnosed Patients with Parkinsons Disease.
    Neurology. 2020 Dec 21. pii: WNL.0000000000011411.
    PubMed     Abstract available


  110. SHIN JH, Lee JY, Kim YK, Shin SA, et al
    Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder.
    Neurology. 2020;95:e3081-e3092.
    PubMed     Abstract available


  111. PYATIGORSKAYA N, Yahia-Cherif L, Valabregue R, Gaurav R, et al
    Parkinson Disease Propagation Using MRI Biomarkers and Partial Least Squares Path Modeling.
    Neurology. 2020 Dec 4. pii: WNL.0000000000011155.
    PubMed     Abstract available


    November 2020
  112. BECKER S, Granert O, Timmers M, Pilotto A, et al
    Association of hippocampal subfields, CSF biomarkers and cognition in non-demented Parkinson's disease patients.
    Neurology. 2020 Nov 20. pii: WNL.0000000000011224.
    PubMed     Abstract available


  113. HIRATA K, Yokota T, Miura Y
    Teaching-Neuroimages: Parkinsonism secondary to a metastatic lesion involving the substantia nigra.
    Neurology. 2020 Nov 9. pii: WNL.0000000000011162.
    PubMed    


    October 2020
  114. WALDVOGEL D, Baumann CR
    Author response: Beware of deep water after subthalamic deep brain stimulation.
    Neurology. 2020;95:760.
    PubMed    


  115. SIDIROPOULOS C
    Reader response: Beware of deep water after subthalamic deep brain stimulation.
    Neurology. 2020;95:759-760.
    PubMed    


  116. WALDVOGEL D, Baumann CR
    Author response: Beware of deep water after subthalamic deep brain stimulation.
    Neurology. 2020;95:759.
    PubMed    


  117. BOUCA-MACHADO R, Neves M, Pona-Ferreira F, Ferreira JJ, et al
    Reader response: Beware of deep water after subthalamic deep brain stimulation.
    Neurology. 2020;95:758-759.
    PubMed    


  118. TAN AH, Lim SY, Chong KK, Azhan A Manap MA, et al
    Probiotics for constipation in Parkinson's disease: A randomized placebo-controlled study.
    Neurology. 2020 Oct 12. pii: WNL.0000000000010998.
    PubMed     Abstract available


  119. LIN CH, Chiu MJ
    Author response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Neurology. 2020;95:658.
    PubMed    


  120. VAN RUMUND A, Marques TM, Esselink RAJ, Bloem BR, et al
    Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Neurology. 2020;95:657-658.
    PubMed    


  121. LEWIS A, Galetta S
    Editors' note: Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Neurology. 2020;95:657.
    PubMed    


  122. FRIEDMAN JH, Goetz CG
    Apathy in Parkinson's disease: Why we should care.
    Neurology. 2020 Oct 1. pii: WNL.0000000000010961.
    PubMed    


  123. SCOTT BM, Eisinger RS, Burns MR, Lopes J, et al
    Co-occurrence of apathy and impulse control disorders in Parkinson's disease.
    Neurology. 2020 Oct 1. pii: WNL.0000000000010965.
    PubMed     Abstract available


    September 2020
  124. CROTTY GF, Maciuca R, Macklin EA, Wang J, et al
    Association of caffeine and related analytes with resistance to Parkinson's disease among LRRK2 mutation carriers: A metabolomic study.
    Neurology. 2020 Sep 30. pii: WNL.0000000000010863.
    PubMed     Abstract available


  125. POSTUMA RB
    Dopamine imaging in prodromal Parkinson disease trials: Ready for prime time?
    Neurology. 2020 Sep 28. pii: WNL.0000000000010957.
    PubMed    


  126. CHUNG SJ, Lee HS, Kim HR, Yoo HS, et al
    Factor analysis-derived cognitive profile predicting early dementia conversion in PD.
    Neurology. 2020;95:e1650-e1659.
    PubMed     Abstract available


    August 2020
  127. COON EA, Mandrekar JN, Berini SE, Benarroch EE, et al
    Predicting phenoconversion in pure autonomic failure.
    Neurology. 2020;95:e889-e897.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: